Principles governing heart failure therapy re-examined relative to standard evidence-based medicine-driven guidelines

References

• Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008, the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J.19, 2388–2442 (2008).
   Google Scholar
• Lindenfeld J, Albert NM, Boehmer JP et al. Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guideline. J. Card. Fail.6, e1–e194 (2010).
   Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. American College of Cardiology Foundation; American Heart Association. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol.53(15), e1–e90 (2009).
   Google Scholar
• Anjaneyulu KSR. Deep bue beats Kasparov in a rematch: a victory for machine over man. Resonance2(7), 89–90 (1997).
   Google Scholar
• Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ; GRADE Working Group. What is ‘quality of evidence’ and why is it important to clinicians? Br. Med. J.336(7651), 995–998 (2008).
   PubMed Web of Science ®Google Scholar
• Kerridge I, Lowe M, Henry D. Ethics and evidence based medicine. Br. Med. J.316(7138), 1151–1153 (1998).
   PubMed Web of Science ®Google Scholar
• Godlee F, Loder E. Missing clinical trial data: setting the record straight. Br. Med. J.341, c5641 (2010).
   Google Scholar
• Clinicians for the Restoration of Autonomous Practice (CRAP) Writing Group. EBM: unmasking the ugly truth. Br. Med. J.325(7378), 1496–1498 (2002).
   PubMedGoogle Scholar
• Cahana A. Ethical and epistemological problems when applying evidence-based medicine to pain management. Pain Pract.4, 298–302 (2005).
   Google Scholar
• Gupta M. A critical appraisal of evidence-based medicine: some ethical considerations. J. Eval. Clin. Pract.2, 111–121 (2003).
   Google Scholar
• Kavanagh BP. 2009 The GRADE System for Rating Clinical Guidelines. PLoS Med.6(9), e1000094 (2010).
   Google Scholar
• Ansari MT, Tsertsvadze A, Moher D. Grading quality of evidence and strength of recommendations: a perspective. PLoS Med.6(9), e1000151 (2009).
   Google Scholar
• Hurwitz B, Richardson R. Swearing to care: the resurgence in medical oaths. Br. Med. J.315(7123), 1671–1674 (1997).
   PubMedGoogle Scholar
• Beauchamp T, Childress J. Principles of Biomedical Ethics (Fifth Edition). Oxford University Press, Oxford, UK (2003).
   Google Scholar
• Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur. J. Heart Fail.3(3), 315–322 (2001).
   PubMed Web of Science ®Google Scholar
• Tan LB, Williams SG, Tan DKH, Cohen-Solal A. So many definitions of heart failure: are they all universally valid? A critical appraisal. Expert Rev. Cardiovasc. Ther.8(2), 217–288 (2010).
   PubMedGoogle Scholar
• Gibson DG. Heart failure – an obsolete term? Eur. Heart J.4(7), 447–448 (1983).
   Google Scholar
• Tan LB, Al-Timman JK, Marshall P, Cooke GA. Heart failure: can it be defined? Eur. J. Clin. Pharmacol.49(Suppl. 1), S11–S18 (1996).
   Google Scholar
• Zib M, Lim L, Walters WA. Symptoms during normal pregnancy: a prospective controlled study. Aus. NZ J. Obstet. Gynaecol.39, 401–410 (1999).
   PubMed Web of Science ®Google Scholar
• Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J. Am. Coll. Cardiol.38(3), 789–795 (2001).
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am. J. Cardiol.91(7), 891–894 (2003).
   PubMed Web of Science ®Google Scholar
• Raphael CE, Whinnett ZI, Davies JE et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart95(1), 56–62 (2009).
   PubMed Web of Science ®Google Scholar
• Tan LB, Lewis N, Ajjan R. Confusion over thiazolidinedione-induced heart failure: need for a better definition of heart failure. Expert Rev. Cardiovasc. Ther.6(5), 623–627 (2008).
   PubMedGoogle Scholar
• Cohn JN, Johnson G, Ziesche S et al. [V-HeFT II] A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med.325, 303–310 (1991).
   PubMed Web of Science ®Google Scholar
• Rector TS, Johnson G, Dunkman WB et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation87, VI71–VI77 (1993).
   PubMedGoogle Scholar
• Bulpitt CJ. Quality of life with ACE inhibitors in chronic heart failure. J. Cardiovasc. Pharmacol.27(Suppl. 2), S31–S35 (1996).
   Google Scholar
• Williams SG, Cooke GA, Wright DJ, Tan LB. Disparate results of ACE inhibitor dosage on exercise capacity in heart failure: a reappraisal of vasodilator therapy and study design. Int. J. Cardiol.77, 239–245 (2001).
   PubMedGoogle Scholar
• Mwaba P, Mwansa J, Chintu C et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad. Med. J.77(914), 769–773 (2001).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients with enalapril: ten year follow-up of CONSENSUS I. Eur. Heart J.20, 136–139 (1999).
   PubMed Web of Science ®Google Scholar
• Rose EA, Gelijns AC, Moskowitz AJ et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) study group. Long-term mechanical left ventricular assistance for end-stage heart failure. N. Engl. J. Med.345(20), 1435–1443 (2001).
   PubMed Web of Science ®Google Scholar
• Tan LB, Murphy R. Shifts in mortality curves: saving or extending lives? Lancet354, 1378–1381 (1999).
   PubMedGoogle Scholar
• Low J, Pattenden J, Candy B, Beattie JM, Jones L. Palliative care in advanced heart failure: an international review of the perspectives of recipients and health professionals on care provision. J. Card. Fail.17, 231–252 (2011).
   PubMed Web of Science ®Google Scholar
• Epstein SE, Braunwald E. β-adrenergic receptor blocking drugs: mechanisms of action and clinical applications. N. Engl. J. Med.275, 1106–1112, 1175–1183 (1966).
   PubMedGoogle Scholar
• Cooke GA, Williams SG, Marshall P et al. A mechanistic investigation of ACE inhibitor dose effects on aerobic exercise capacity in heart failure patients. Eur. Heart J.23, 1360–1368 (2002).
   PubMedGoogle Scholar
• Carluccio E, Biagioli P, Alunni G et al. Effect of revascularizing viable myocardium on left ventricular diastolic function in patients with ischaemic cardiomyopathy. Eur. Heart J.30(12), 1501–1509 (2009).
   PubMedGoogle Scholar
• Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power in heart failure. Curr. Opin. Cardiol.18(3), 215–222 (2003).
   PubMed Web of Science ®Google Scholar
• Goldspink DF, Burniston JG, Tan LB. Cardiomyocyte death and the ageing and failing heart. Exp. Physiol.88(3), 447–458 (2003).
   PubMed Web of Science ®Google Scholar
• Sonnenblick EH. Implications of muscle mechanics in the heart. Fed. Proc.21, 975–990 (1962).
   PubMedGoogle Scholar
• Williams SG, Barker D, Goldspink DF, Tan LB. A reappraisal of concepts in heart failure: Central role of cardiac power reserve. Arch. Med. Sci.1, 65–74 (2005).
   Google Scholar
• Harris P. Evolution and the cardiac patient. Cardiovasc. Res.17(7), 437–445 (1983).
   PubMed Web of Science ®Google Scholar
• Nicholls DP, Onuoha GN, McDowell G et al. Neuroendocrine changes in chronic cardiac failure. Basic Res. Cardiol.91(Suppl. 1), 13–20 (1996).
   PubMed Web of Science ®Google Scholar
• Iravanian S, Dudley SC Jr. The renin–angiotensin–aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm5(6 Suppl.), S12–S17 (2008).
   Web of Science ®Google Scholar
• Kajstura J, Cigola E, Malhotra A et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J. Mol. Cell. Cardiol.29, 859–870 (1997).
   PubMed Web of Science ®Google Scholar
• Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ. Res.69, 1185–1195 (1991).
   PubMed Web of Science ®Google Scholar
• Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ. Res.65, 657–670 (1989).
   PubMed Web of Science ®Google Scholar
• Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ. Res.64, 1041–1050 (1989).
   PubMed Web of Science ®Google Scholar
• Tan LB, Schlosshan D, Barker D. Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. Int. J. Cardiol.96, 321–333 (2004).
   PubMedGoogle Scholar
• Feinstein AR. The need for humanised science in evaluating medication. Lancet2, 421–423 (1972).
   PubMed Web of Science ®Google Scholar
• Feinstein AR. ‘Clinical judgment’ revisited: the distraction of quantitative models. Ann. Intern. Med.120(9), 799–805 (1994).
   PubMed Web of Science ®Google Scholar